{"id":"W2921560039","doi":"10.1200/jco.2019.37.7_suppl.350","title":"Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Bladder cancer; Cohort; Pembrolizumab; Cystectomy; Internal medicine; Clinical endpoint; Urology; Cancer; Carcinoma in situ; Discontinuation; Surgery; Oncology; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303134,0.001296397,0.0009456231,0.0002932517,0.0002996166,0.000899647,0.00099889,0.001208412,0.007352477],"category_scores_gemma":[0.0008232308,0.000419094,0.0007404623,0.0003423974,0.0005560041,0.0009383341,0.0005012837,0.002859047,0.001499628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009031296,"about_ca_system_score_gemma":0.001322456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007332888,"about_ca_topic_score_gemma":0.002043155,"domain_scores_codex":[0.9997326,0.0001290387,0.00001339042,0.00004369174,0.00002642744,0.00005491273],"domain_scores_gemma":[0.9996351,0.00005428963,0.00009297243,0.00002610734,0.00002055166,0.0001710674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8145851,0.03056953,0.005891295,0.00216503,0.001248465,0.0003785902,0.0002332166,0.002455817,0.03291041,0.0006901004,0.01268218,0.09619027],"study_design_scores_gemma":[0.8060232,0.1786427,0.007378188,0.00007447644,0.0003980584,0.0003056399,0.0000487099,0.0008114949,0.002203437,0.0002327787,0.003863332,0.00001802455],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768028,0.004145166,0.0008797103,0.001072599,0.0002400773,0.005291118,0.004926933,0.0002548656,0.006386758],"genre_scores_gemma":[0.9727443,0.003210532,0.002079468,0.001962841,0.0002718267,0.005066415,0.008059692,0.00004122131,0.006563704],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007352477,"threshold_uncertainty_score":0.02459645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.062360026302153,"score_gpt":0.4304039094293898,"score_spread":0.3680438831272368,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}